Skip to main content

Advertisement

ADVERTISEMENT

Interactive Features

Quiz
10/17/2022
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy...
10/17/2022
Oncology
Test Your Knowledge
09/08/2021
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon...
09/08/2021
Oncology
Test Your Knowledge
09/08/2021
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon...
09/08/2021
Oncology

Advertisement

Quiz
08/09/2021
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination...
08/09/2021
Oncology
Test Your Knowledge
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
08/28/2020
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did...
08/28/2020
Oncology

Advertisement

Test Your Knowledge
08/21/2020
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with...
08/21/2020
Oncology
Test Your Knowledge
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology
Test Your Knowledge
07/31/2020
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival...
07/31/2020
Oncology

Advertisement

Test Your Knowledge
06/22/2020
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma...
06/22/2020
Oncology

Advertisement